|
1. Biologie
|
|
|
How Kidney Cancer Evolves [The Scientist]
|
|
|
|
|
|
“In
evolutionary biology, there’s been this conflict for quite some time
between the punctuated evolutionists and the Darwinian evolutionists,”
Swanton tells The Scientist. “I think what we’re seeing in cancer
evolution is that both these models describe distinct clinical
phenotypes of tumors.”
|
|
|
|
|
|
|
|
|
4. Dépistage, diagnostic et pronostic
|
|
|
Scientists create a biomedical tattoo to monitor for a sign of cancer [STAT]
|
|
|
|
|
|
The
idea would still need to be studied further in animals and in patients
before it could ever be used in the clinic. If it worked in humans,
Fussenegger said the tool might be useful for monitoring people at an
increased risk of certain types of cancer that change calcium levels or
in cancer survivors to monitor for new tumors.
|
|
|
|
|
|
|
|
4.10 Dép., diag. & prono. - Poumon
|
|
|
|
4.2 Dép., diag. & prono. - Génome
|
|
|
|
5. Traitements
|
|
|
|
5.1 Traitements - Pré-clinique
|
|
|
|
5.12.3 Immunothérapies-combinaisons
|
|
|
|
5.12.5 Immunothérapies - Pharma
|
|
|
|
Surface Oncology’s Upsized IPO Reels in $108M for Lead Cancer Drug [Xconomy]
|
|
|
|
|
|
Surface
develops drugs to block a protein that is overabundant on the surface
of tumors. This protein, CD47, helps tumors fight off attack from immune
cells. In preclinical research, Surface reported that macrophages, a
type of immune cell, showed greater tumor-destroying activity in the
drug’s presence.
|
|
|
|
|
|
|
5.12.8 Immunothérapies - Economie
|
|
|
|
5.2 Pharma
|
|
|
|
|
5.2.2 Pharma - Fusions & Acquisitions
|
|
|
|
|
|
5.2.3 Pharma - économie
|
|
|
|
5.3 Traitements - FDA, EMA, NICE...
|
|
|
|
5.3.4 Traitements - AMM (FDA, EMA,...)
|
|
|
|
|
|
Brentuximab Approved for Initial Treatment of Advanced Hodgkin Lymphoma [NCI]
|
|
|
|
|
|
Longer
follow-up will be required to determine whether the improved efficacy
is maintained over time and to rule out late side effects, wrote Dan
Longo, M.D., of the Dana-Farber Cancer Institute and Vincent DeVita,
Jr., M.D., of the Yale Cancer Center, in an editorial that accompanied
the ECHELON-1 results.
|
|
|
|
|
|
|
5.4 Traitements - Economie
|
|
|
|
5.9 AACR
|
|
|
|
5.9.4 AACR - poumon
|
|
|
|
Merck Immunotherapy Drug Shines In Lung Cancer Study [NPR]
|
|
|
|
|
|
Herbst
said medical researchers didn't immediately think of combining
chemotherapy with immunotherapy because it seemed odd to try to use
chemicals to kill the cancer cells that the immune system was also
supposed to be hunting down. But it turns out to be a reasonable
strategy.
|
|
|
|
|
|
|
|
5.9.9 AACR - immunothérapies
|
|
|
|
|
|
6.1 Observation
|
|
|
Married People Less Likely to Die From Melanoma [NY Times]
|
|
|
|
|
|
After
controlling for age, sex, education level and other factors, the
researchers found that 46 percent of married people went to a doctor at
the earliest stage of the disease, compared with 43 percent of the never
married, 39 percent of the divorced, and 32 percent of the widowed.
|
|
|
|
|
|
|
6.5 Médecines alternatives
|
|
|
|
6.6 Publications
|
|
|
|
6.7.1 IA/bioinformatique
|
|
|
Google's New AI Head Is So Smart He Doesn't Need AI [Wired]
|
|
|
|
|
|
Dean
wouldn’t discuss details. But two Google research projects offer clues.
The company is testing software in India that can detect a complication
of diabetes that causes blindness, and has also tested software that
looks for signs of breast cancer on microscope slides.
|
|
|
|
|
|